Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib



Data Article

Dataset of cocoa aspartic protease cleavage sites



Katharina Janek^a, Agathe Niewienda^a, Johannes Wöstemeyer^b, Jürgen Voigt^{b,*}

^a Charité – University Medicine Berlin, Institute of Biochemistry, D-10117 Berlin, Germany ^b Friedrich-Schiller-University Jena, Chair of General Microbiology and Microbial Genetics, D-07743 Jena, Germany

ARTICLE INFO

Article history: Received 9 May 2016 Received in revised form 30 May 2016 Accepted 14 June 2016 Available online 24 June 2016

Keywords: Aspartic protease Cleavage sites Cocoa In-vitro proteolysis Mass spectrometry Peptides

ABSTRACT

The data provide information in support of the research article, "The cleavage specificity of the aspartic protease of cocoa beans involved in the generation of the cocoa-specific aroma precursors" (Janek et al., 2016) [1]. Three different protein substrates were partially digested with the aspartic protease isolated from cocoa beans and commercial pepsin, respectively. The obtained peptide fragments were analyzed by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF-MS/MS) and identified using the MASCOT server. The N- and C-terminal ends of the peptide fragments were used to identify the corresponding *in-vitro* cleavage sites by comparison with the amino acid sequences of the substrate proteins. The same procedure was applied to identify the cleavage sites used by the cocoa aspartic protease during cocoa fermentation starting from the published amino acid sequences of oligopeptides isolated from fermented cocoa beans.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Specifications Table

Subject area More specific subject area Biochemistry Protease cleavage specificity

DOI of original article: http://dx.doi.org/10.1016/j.foodchem.2016.05.033

* Corresponding author.

http://dx.doi.org/10.1016/j.dib.2016.06.021

2352-3409/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

E-mail address: juergen.voigt@uni-jena.de (J. Voigt).

Type of data	Tables
How data was acquired	Peptide mixtures obtained by cleavage of different substrate proteins with purified cocoa aspartic protease or pepsin were analyzed by liquid chromatography- MALDI-TOF/TOF-MS/MS using a 4700 proteomics Analyzer (Applied Biosystems, Framingham,MS) of-line coupled with a Ultimate HPLC system and Probot frac- tionation devise (both Dionex/Thermo, Idstein, Germany). Amino acid sequences of
	oligopeptides isolated from fermented cocoa beans were taken from the literature.
Data format	Analyzed
Experimental factors	Samples were prepared by partial digestion of different substrate proteins with purified cocoa aspartic protease or pepsin. Prior to LC-MALDI-MS/MS analyses, the peptide mixtures were modified by reduction and alkylation of cysteine residues with dithiotreitol and iodoacetamide.
Experimental features	Generation of oligopeptide mixtures by digestion of substrate proteins with pur- ified cocoa aspartic protease or pepsin, fractionation and sequencing of the pep- tides by LC-MALDI-TOF/TOF-MS/MS and subsequent identification of the cleavage sites. Data were compared with the cleavage sites predicted from the sequences of oligopeptides isolated from fermented cocoa beans and analyzed by liquid chromatography-tandem mass spectrometry. The abundance of the different amino acid residues in the P4-P4' positions around the cleavage sites were ana- lyzed to get an insight into the particular cleavage specificity of the cocoa aspartic protease.
Data source location	Berlin, Germany, and Jena, Germany
Data accessibility	Data are within this article.

Value of the data

- 1. These data characterize the cleavage sites of the cocoa aspartic protease.
- 2. Characterization of the cleavage specificity of an endoprotease requires the comparative analysis of the amino acid sequences around many of its cleavage sites.
- 3. We provide a strategy enabling the discrimination between specific and unspecific cleavage sites of an endoprotease.
- Our data demonstrate the limitation of the identification of protease cleavage sites by LC-MALDI-TOF/TOF-MS/MS versus ESI-MS/MS.
- 5. These data will contribute to our knowledge concerning the formation of the cocoa-specific aroma precursors.

1. Data

Three tables are presented. Table 1 contains the cleavage sites in different substrate proteins used by the cocoa aspartic protease and pepsin, respectively, identified by *in-vitro* proteolysis. Table 2 shows the putative cleavage sites of the cocoa aspartic protease used during commercial cocoa fermentation. Table 3 shows the abundance of the different amino acids in the P4 to P4' positions around the cleavage sites used by the cocoa aspartic protease during *in-vitro* proteolysis and cocoa fermentation, respectively.

Table 1

Specific and common cleavage sites of cocoa aspartic protease and pepsin in different protein substrates^a.

Substrate	Cleavage sites specific for the cocoa protease		Common cleavage sites of cocoa protease and pepsin		Cleavage sites specific for pepsin	
	P4-P4′	Position	P4-P4′	Position	P4-P4′	Position
Myoglobin (SwissProt no. P68082)	EWQQIVLNV	7-14	DGEWIQQVL	5-12	GEWQIQVLN	6-13
	WQQVILNVW	8-15	QQVLINVWG	9-16	VLNVIWGKV	11-18
	FDKF KHLK	44-51	LNVWIGKVE	12-19	NVWG KVEA	13-20
	LKTE AEMK	50-57	HGQEIVLIR	25-32	GKVE ADIA	16-23
	EDLK KHGT	60-67	GQEVILIRL	26-33	KVEA DIAG	17-24
	AIIHIVLHS	111-118	QEVLIRLF	27-34	VEADIIAGH	18-25
	IHVLIHSKH	113-120	LIRLIFTGH	30-37	AGHGIQEVL	23-30
	HVLHISKHP	114-121	TVVLITALG	67-74	GHGQIEVLI	24-31
	VLHSIKHPG	115-122	PIKYILEFI	101-108	EVLI RLFT	28-35
	HPGDIFGAD	120-127	KYLE FISD	103-110	PETLIEKFD	38-45
	FRNDIIAAK	139-146	YLEFIISDA	104-111	HLKTIEAEM	49-56
	AKYK ELGF	145-152	FISDIAIIH	107-114	KTEAIEMKA	51-58
	YKELIGFQG	147-154	ISDAIIIHV	108-115	EAEMIKASE	53-60
			MTKA LELF	132-139	GGILIKKKG	74-81
			ALELIFRND	135-142	EAEL KPLA	84-91
			KYKE LGFQ	146-153	PGDFIGADA	121-128
					QGAMITKAL	129-136
					GAMT KALE	130–137
					TKALIELFR	133-140
					KALE LFRN	134-141
					LELF RNDI	136-143
					AAKY KELG	144–151
					ELGFIQD	149–154
Cocoa 21-kDa seed protein (SwissProt no. P32765)	GGLAILGRA	57-64	VANAIANSP	23-30	GRATIGQSC	62-69
	GLALIGRAT	58-65	YYVLISSIS	45-52	CPEIIVVQR	69-76
	ATGQISCPE	64-71	EIVVIQRRS	71–78	VRVSITDVN	98-105
	GKWWIVTTD	132-139	IVVQ RRSD	72-79	NIEF VPIR	105-112
	GYKF RFCP	163-170	PVIFISNAD	85-92	PIRDIRLCS	110-117
	KFRF CPSV	165-172	VIFSINADS	86-93	TSTV WRLD	118-125
			AGKW WVTT	131-138	AGVLIGYKF	159–166
			PNTLICSWF	147-154	SVCDISCTT	171–178
			TLCS WFKI	149-156	SDDDIGQIR	187–194
			LCSWIFKIE	150-157	IRLA LSDN	193-200
			CSWF KIEK	151-158	RLALISDNE	194-201
			QIRLIALSD	192-199		
			ASKTIIKQV	209-216		
Cocoa vicilin (TrEMBL no. A0A061EM85)	NDYRILAMF	50–57	PKRRISFQT	17–24	RSEEIEEGQ	1–8
	ENKEISYNV	91–98	RRSFIQTRF	19–26	PYYFIPKRR	13–20
	TVYVIVSQD	111–118	EGNFIKILQ	30-37	YYFP KRRS	14-21
	GMFR KAKP	190–197	FKILIQRFA	33-40	YFPK RRSF	15-22
	KAKPIEQIR	194-201	LQRFIAENS	36-43	RSFQ /TRFR	20-27
	AKPEIQIRA	195-202	KGINIDYRL	47-54	FQTRIFRDE	22–29
	KPEQIIRAI	196-203	GINDIYRLA	48-55	QTRFIRDEE	23-30
	ERLAIINLL	216-223	DYRLIAMFE	51-58	KILQIRFAE	34-41
	FKLNIQGAI	257-264	RLAMIFEAN	53-60	ILQRIFAEN	35-42
	VPHYINSKA	266-273	CDAEIAIYF	70–77	NPNT FILP	60-67
	GYAQIMACP	284-291	EAIYIFVTN	73-80	DAEAIIYFV	71–78
	VTFFIASKD	343-350	TITFIVTHE	84-91	AEAIIYFVT	72–79
	LVDNIIFNN	395-402	TVVSIVPAG	102-109	AIYFIVTNG	74-81
			SVPAIGSTV	105-112	GTIT FVTH	83-90
			STVYIVVSQ	110–117	VTHEINKES	88-95
			TIAVILALP	124-131	KESYINVQR	93-100
			VLALIPVNS	127-134	ESYN/VQRG	94-101

 Table 1 (continued)

Substrate	Cleavage sites specific for the cocoa protease		Common cleav cocoa protease	Common cleavage sites of cocoa protease and pepsin		Cleavage sites specific for pepsin	
	P4–P4 ′	Position	P4-P4′	Position	P4-P4′	Position	
Substrate	Cleavage sit the cocoa p P4–P4'	es specific for rotease Position	Common cleax cocca protease P4-P4' KYELIFFPA ELFFIPAGN NKPEISYYG YGAFISYEV YEVLIETVF REKLIEEIL KLEEIILEE EEILIEEQR QIRAIISQQ GERLIAINL AINULSQS NGRFIFEAC AVSAIFKLN NQGAIIFVP KATFIVVFV SGRQIDRREQ RQDRIREQE ECTFIGEFQ TFGEIFQQVK GDVFIVAPA AVTFIFASK AVAFIGLNA QRIFILAGK KKNLIVRQM EAKEILSFG FSKLIVDNI ESYFIMSFS	Agge sites of e and pepsin Position 137-144 139-146 147-154 153-160 158-165 169-176 171-178 173-180 199-206 215-222 219-226 233-240 260-267 272-279 302-309 303-310 304-311 316-323 318-325 319-326 332-339 342-349 355-362 366-373 373-380 383-390 392-399 405-412	Cleavage site: for pepsin P4–P4' YNVQIRGTV VQRGTVVS RGTVI/SVPA VVSVIPAGS AGSTI/VVSV GTV/ISVPA VVSVIPAGS AGSTI/VVS LTIA/VLAL IAVLIALPV PGKYIELFF GKYEILFF GKYEILFF GKYEILFF GKYEILFF GKYEILFF GKYEILFF GKYEILFF GKYEILFF GAFSIYEVL AFSYIEVLE FSYEIVLET EVLEITVFN ETVFINTQR QQGMIFRKAK LAINILLSQ INLLISQSP GRFFIEACP FSQFIQNMD VSAFIKLNQ AFKLINQGA GAIFIVPHY FVVFIVTDG CPHLISRQS SRQSIQGSQ SQQSIQSQR QGSQISGRQ GSQSGRQD SQSGIRQDR EEETIFGEF PGDVIFVAP PLNAIVAFG NAVAIFGLN ARIFLAGKK IFLAIGKK	s specific 96-103 98-105 100-107 101-108 103-110 108-115 109-116 123-130 125-132 135-142 136-143 138-145 149-156 152-159 154-161 155-162 156-163 159-166 162-169 188-195 189-196 218-225 220-227 234-241 244-251 254-261 256-263 262-269 275-282 290-297 294-301 254-261 256-263 262-269 275-282 290-297 294-301 295-302 297-304 298-305 299-306 300-307 315-322 331-338 352-359 354-361 357-364 357-374 368-375	
					FGLNIAQNN NNQRIIFLA RIFLIAGKK	358-365 364-371 367-374	
					IFLAIGKKN FLAGIKKNL VRQMIDSEA RQMDISEAK QMDSIEAKE MDSEIAKEL GVPSIKLVD DNIFINNPD	368–375 369–376 377–384 378–385 379–386 380–387 390–397 397–404	
					NNPDIESYF PDESIYFMS SQQRIQRGD QQRQIRGDE	401–408 403–410 412–419 413–420	

^a Octapeptide sequences around the cleavage sites for the cocoa aspartic protease and pepsin, respectively, detected by partial proteolysis of myoglobin, the cocoa 21-kDa seed protein, and the cocoa vicilin-class(7S) globulin. Data were separately listed for sites exclusively cleaved by the cocoa aspartic protease and pepsin, respectively, and those cleaved by both proteases (=unspecific cleavage sites).

Table 2

Putative cleavage sites of the cocoa aspartic protease predicted from oligopeptides isolated from fermented cocoa beans.

Substrate	Putative cleavage site ^a	Position ^b	N- or C-terminal localiza- tion of the cleavage site ^c	Cleavage site also detected <i>in vitro</i> [1]	References
Cocoa 21-kDa seed protein (SwissProt no. P32765)	VANAIANSP	23-30	N-terminal	yes	[3]
	SPVLIDTDG	29-36	C-terminal	no	[3]
	YYVLISSIS	45-52	N-terminal	yes	[3]
	SSISIGAGG	49-56	N-terminal	no	[3]
	GGGLIALGR	56-63	C-terminal	no	[3]
	IVVQ RRSD	72–79	N-terminal	yes	[3]
	SDLDINGTP	78-85	N-terminal	no	[3]
	PVIFISNAD	85-92	N- and C-terminal	no	[3]
	FSNAIDSKD	88-95	N-terminal	no	[3]
	DVVR VSTD	96-103	N-terminal	no	[3]
	TDVNIIEFV	102-109	N- and C-terminal	no	[3]
	NIEF VPIR	105–112	C-terminal	no	[3]
	CSTS TVWR	116-123	N-terminal	no	[3]
	STVW RLDN	119-126	N-terminal	no	[3]
	WRLDINYDN	122-129	C-terminal	no	[3]
	LALSIDNEW	195-202	N-terminal	no	[3]
	AWMFIKKAS	203-210	C-terminal	no	[3]
Cocoa vicilin (TrEMBL no. A0A061EM85)	EGQQIRNNP	6–13	N- and C-terminal	no	[3,4]
	GOORINNPY	7–14	N-terminal	no	[3,4]
	QQRNINPYY	8-15	N-terminal	no	[4]
	ORNNIPYYF	9-16	N-terminal	no	[4]
	PYYFIPKRR	13-20	C-terminal + CP	no	[4]
	YFPK RRSF	15-22	N- and C-terminal	no	[3,4]
	FPKR RSFQ	16-23	N-terminal	no	[4]
	RRSFIQTRF	19-26	C-terminal	ves	[3,4]
	RSFOITRFR	20-27	N-terminal	no	[3]
	TRFRIDEEG	24-31	N-terminal	no	[3]
	RDEEIGNFK	27-34	N- and C-terminal	no	[3,4]
	EEGNIFKIL	29-36	N-terminal	no	[3]
	EGNFIKILQ	30-37	N- and C-terminal	yes	[3,4]
	FKILIQRFA	33-40	C-terminal	yes	[3]
	KILQIRFAE	34-41	C-terminal	no	[4]
	SPPLIKGIN	43-50	N-terminal	no	[4]
	KGINIDYRL	47-54	C-terminal	ves	[4]
	INDY RLAM	49-56	N-terminal	no	[4]
	RLAM FEAN	53-60	C-terminal + CP	yes	[4]
	NPNT FILP	60-67	N-terminal	no	[4]
	ILPH HCDA	65-72	C-terminal	no	[4]
	YFVT NGKG	76-83	N-terminal	no	[3]
	VTNG KGTI	78-85	N-terminal	no	[4]
	TITFIVTHE	84-91	C-terminal \pm CP	yes	[3,4]
	THEN KESY	89-95	N-terminal	no	[3]
	YNVQIRGTV	96-103	N- and C-terminal	no	[3,4]
	TVVSIVPAG	102-109	C-terminal	yes	[4]
	VLALIPVNS	127-134	N-terminal	yes	[4]
	LPVNISPGK	129-138	N-terminal	no	[4]
	PGKY ELFF	135-142	C-terminal	no	[4]
	FPAGINNKP	142-149	N-terminal	no	[3]
	AGNN IKPES	144–151	N-terminal	no	[4]
	NKPEISYYG	147-154	C-terminal	no	[3]
	KPES YYGA	148-155	N- and C-terminal	no	[3,4]
	FSYE VLET	156-163	N-terminal	no	[3]
	YEVL ETVF	158-167	C-terminal	yes	[3]
	EVLE TVFN	159-166	C-terminal	no	[3]
	PRHR GGER	209-217	N-terminal	no	[4]

 Table 2 (continued)

site ^a		tion of the cleavage site ^c	detected in vitro [1]	
ERLAIINLL 21	6-223	N-terminal	yes	[4]
AINLILSQS 21	9-226	C-terminal+CP	yes	[4]
INLLISQSP 22	20-227	C-terminal	no	[4]
NLLSIQSPV 22	21-228	C-terminal	no	[4]
VAVSIAFKL 25	2-259	N-terminal	no	[4]
AVSAIFKLN 25	3-260	N-terminal	yes	[4]
FKLNIQGAI 25	57-264	C-terminal+CP	yes	[4]
KLNQIGAIF 25	8-265	N- and C-terminal	no	[4]
LNQGIAIFV 25	9-266	N-terminal	no	[4]
NQGAIIFVP 26	60-267	N- and C-terminal	yes	[4]
QGAIIFVPH 26	61-268	N-terminal	no	[4]
GAIFIVPHY 26	52-269	N-terminal	no	[4]
VPHYINSKA 26	6-273	C-terminal+CP	yes	[4]
PHYNISKAT 26	57-274	C-terminal	no	[4]
HYNSIKATF 26	68-275	C-terminal	no	[4]
KATFIVVFV 27	2-279	C-terminal+CP	yes	[4]
SQSGIRQDR 30	0–307	N-terminal	no	[3]
EQEEIESEE 30	9-316	C-terminal	no	[3]
GEFQIQVKA 32	20-327	N-terminal	no	[4]
QQVKIAPLS 32	23-330	N-terminal	no	[3]
KAPLISPGD 32	26-333	N- and C-terminal	no	[3,4]
APLSIPGDV 32	27-334	N-terminal	no	[3]
PLSPIGDVF 32	28-335	N-terminal	no	[3]
GDVFIVAPA 33	32-339	N- and C-terminal	yes	[3,4]
VFVAIPAGH 33	84-341	N-terminal	no	[3]
APAGIHAVT 33	37-344	N-terminal	no	[4]
AVTFIFASK 34	2-349	C-terminal	yes	[3,4]
VTFFIASKD 34	3-350	N- and C-terminal	yes	[3,4]
FFASIKDQP 34	5-352	N-terminal	no	[3]
FASKIDQPL 34	6-353	N-terminal	no	[4]
AVAFIGLNA 35	5-362	C-terminal+CP	yes	[3,4]
LNAQINNQR 36	60-367	N-terminal	no	[4]
NAQNINQRI 36	61-368	N-terminal	no	[4]
AQNNIQRIF 36	52-369	N-terminal	no	[4]
QNNQIRIFL 36	3-370	N-terminal	no	[4]
QRIFILAGK 36	6-373	C-terminal	no	[4]
GKKNILVRQ 37	2-379	N-terminal	no	[4]
NLVRIQMDS 37	5-382	C-terminal	no	[4]
AKELISFGV 38	34-391	N-terminal	no	[4]
KELSIFGVP 38	35-392	N-terminal	no	[4]
PSKLIVDNI 39	2-399	C-terminal+CP	no	[4]
NPDEISYFM 40	02-409	N-terminal	no	[4]
ESYFIMSFS 40	05-412	C-terminal	no	[4]

^a Octapeptide sequence (P4–P4') around the putative cleavage site.

^b Position of the octapeptide in the amino acid sequence of the degraded seed protein.

^c Localization of the cleavage site at the N-terminal or C-terminal end of the oligopeptide, from which the cleavage site was predicted. Since the peptides formed during cocoa fermentation are modified by a carboxypeptidase [2,5], the N-terminal cleavage sites are more reliable than the C-terminal ones. In case of the C-terminal ends of the corresponding oligopeptide, a downstream localized cleavage site was predicted, whenever the resulting peptide fragment could be modified by the cocoa carboxypeptidase [6] to the finally detected oligopeptide (indicated by "+CP").

2. Experimental design, materials and methods

2.1. Determination of cleavage sites by in-vitro proteolysis

Cocoa protease, the cocoa 21-kDa seed protein, and the cocoa vicilin-class(7S) globular storage protein were isolated from the acetone-dry powder of unfermented cocoa beans essentially as

Table 3

Abundance of different amino acid residues in the P4 to P4' positions of the predicted and experimentally detected cleavage sites of the cocoa aspartic protease.

	P4 ^a		P3 ^a		P2 ^a		P1 ^a	
	In-situ ^{b,d}	In-vitro ^{c,d}	In-situ ^{b,d}	In-vitro ^{c,d}	In-situ ^{b,d}	In-vitro ^{c,d}	In-situ ^{b,d}	In-vitro ^{c,d}
w	1.02	0.93	1.02	0.93	0.00	1.88	1.02	4.67
F	8.16	6.54	4.08	1.88	4.08	3.76	15.30	20.56
Y	5.10	4.67	3.06	6.54	4.08	3.76	3.06	3.76
L	4.08	5.61	7.14	8.41	11.32	5.54	12.24	20.56
I	4.08	2.80	4.08	11.32	6.12	6.54	1.02	0.00
Μ	0.00	0.93	0.00	0.93	1.02	0.00	1.02	0.93
v	7.14	5.61	8.16	10.29	16.32	11.32	0.00	4.67
Α	10.20	10.28	8.16	4.67	8.16	7.48	6.12	8.49
G	6.12	10.28	7.14	9.34	3.06	3.76	5.10	0.00
С	1.02	1.88	0.00	0.93	0.00	0.93	0.00	0.00
Т	5.10	6.54	3.06	3.76	4.08	5.54	2.04	0.93
S	6.12	2.80	7.14	4.67	5.10	3.76	11.22	3.76
Q	6.12	4.67	7.14	5.54	4.08	3.76	9.18	5.54
N	8.16	3.76	6.12	2.80	12.24	4.67	13.26	2.80
Ε	7.14	11.20	4.08	5.54	6.12	8.49	6.12	10.28
D	1.02	1.88	4.08	4.67	2.04	2.80	2.04	4.67
Н	1.02	2.80	2.04	0.93	2.04	1.88	1.02	1.88
R	4.08	3.74	7.14	4.67	1.02	9.34	6.12	3.76
К	7.14	9.34	5.10	9.34	4.08	11.32	3.06	1.88
Р	7.14	3.74	11.22	2.80	5.10	2.80	1.02	0.93
	P1 ′ ^a		P2 ′ ^a		P3 ′ ^a		P4 ′ ^a	
	P1' ^a In-situ ^{b,d}	<i>In-vitro</i> ^{c,d}	P2' ^a In-situ ^{b,d}	In-vitro ^{c,d}	P3' ^a In-situ ^{b,d}	<i>In-vitro</i> ^{c,d}	P4' ^a In-situ ^{b,d}	In-vitro ^{c,d}
	P1 ^{/a} <i>In-situ</i> ^{b,d}	<i>In-vitro</i> ^{c,d}	P2' ^a <i>In-situ</i> ^{b,d} 0.00	<i>In-vitro</i> ^{c,d}	P3 ^{'a} <i>In-situ</i> ^{b,d}	<i>In-vitro</i> ^{c,d}	P4 ′ ^a <i>In-situ</i> ^{b,d}	<i>In-vitro</i> ^{c,d}
W F	P1' ^a <i>In-situ</i> ^{b,d} 0.00 7.14	<i>In-vitro^{c,d}</i> 1.88 11.22	P2 ′ ^a <i>In-situ</i> ^{b,d} 0.00 4.08	<i>In-vitro</i> ^{c,d} 0.00 6.54	P3 ^{'a} <i>In-situ</i> ^{b,d} 1.02 12.24	<i>In-vitro^{c,d}</i> 1.88 7.48	P4 ^{<i>i</i>} <i>In-situ</i> ^{b,d} 1.02 9.18	<i>In-vitro</i> ^{c,d} 0.93 7.48
W F Y	P1' ^a <i>In-situ</i> ^{b,d} 0.00 7.14 1.02	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93	P2' ^a In-situ ^{b,d} 0.00 4.08 6.12	<i>In-vitro</i> ^{c.d} 0.00 6.54 3.76	P3' ^a <i>In-situ</i> ^{b,d} 1.02 12.24 3.06	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88	P4' ^a <i>In-situ</i> ^{b,d} 1.02 9.18 4.08	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00
W F Y L	P1 ^{/a} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28	P2' ^a In-situ ^{b,d} 0.00 4.08 6.12 6.12	In-vitro ^{c,d} 0.00 6.54 3.76 6.54	P3 ′ ^a <i>In-situ</i> ^{b,d} 1.02 12.24 3.06 5.10	<i>In-vitro^{c,d}</i> 1.88 7.48 1.88 8.41	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12	<i>In-vitro^{c,d}</i> 0.93 7.48 0.00 5.66
W F Y L I	P1 ^{/a} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28	P2' ^a In-situ ^{b,d} 0.00 4.08 6.12 6.12 4.08	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08	<i>In-vitro^{c,d}</i> 0.93 7.48 0.00 5.66 4.67
W F Y L I M	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 1.88	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04	In-vitro ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93
W F Y L I M V	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 1.88 11.21	P2' ^a 	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41
W F Y L I M V A	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 1.88 11.21 8.41	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28	P3' ^a <i>In-situ</i> ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41
W F Y L I M V A G	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 3.06 1.02 9.18 6.12 6.12 6.12	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 1.88 11.21 8.41 5.66	P2' ^a In-situ ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16 9.18	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76	P3' ^a <i>In-situ</i> ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12	<i>In-vitro</i> ^{c.d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 8.41 6.54
W F L I M V A G C	P1 ^{/4} In-situ ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 6.12 0.00	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 4.08 1.02 7.14 8.16 9.18 1.02	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93	P3' ^a <i>In-situ</i> ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 0.00 .00	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 6.12 0.00	<i>In-vitro</i> ^{c.d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93
W F Y L I M V A G C T	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 0.00 3.06 3.06 1.02 9.18 6.12 0.00 3.06 3.06 5.12 6.12 5.12	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 4.08 1.02 1.02 4.08 1.02	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 0.00 5.10	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76
W F Y L I M V A G C T S	P1 ^{/4} In-situ ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 0.00 3.06 9.18	<i>In-vitro</i> ^{c.d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.26 1.88 11.21 8.41 5. 666 1.88 0.93 7.48	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 1.02	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 0.00 5.10 6.12	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48
W F Y L I M V A G C T S Q	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 6.12 6.12 0.00 3.06 9.18 7.14	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 11.21 8.41 5. 666 1. 88 0. 93 7.48 6.54	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 10.20 4.08 10.20 4.08 10.20 4.08 10.20 4.08 10.20 4.08 10.20 4.08 10.20	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 0.00 5.10 6.12 3.06	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54 9.34	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06	<i>In-vitro</i> ^{c.d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66
W F Y L I M V A G C T S Q N	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 6.12 0.00 3.06 9.18 7.14 9.18	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.5 10.6 1.88 11.21 8.41 5.66 1.88 0.93 7.48 6.54 2.80	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 10.20 4.08 9.18	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76 3.76 3.76	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 8.16 0.00 5.10 6.12 3.06 4.08 4.08	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54 9.34 8.41	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06 6.12	<i>In-vitro</i> ^{c.d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66 4.67
W F Y L I M V A G C T S Q N E	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 6.12 0.00 3.06 9.18 7.14 9.18 3.06	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 188 11.21 8.41 5.66 1.88 0.93 7.48 6.54 2.80 4.67	P2' ^a In-situ ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 10.20 4.08 9.18 4.08 9.18 4.08 9.18 4.08 9.18 4.08 9.18 4.08 9.18 4.08 9.18 4.08 9.18	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76 3.76 9.34	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 8.16 0.00 5.10 6.12 3.06 4.08 6.12	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54 9.34 8.41 3.76	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06 6.12 3.06	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66 4.67 7.48
W F Y L I M V A G C T S Q N E D	P1 ^{/4} In-situ ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 0.00 3.06 9.18 7.14 9.18 3.06 6.12 	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 13.88 11.21 8.41 5.66 1.88 0.93 7.48 6.54 2.80 4.67 1.88	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 5.16 5.18 4.08 5.18	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76 9.34 0.93	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 8.16 8.16 0.00 5.10 6.12 3.06 4.08 6.12 7.14	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54 9.34 8.41 3.76 1.88	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06 6.12 3.06 6.12 3.06 6.12	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66 4.67 7.48 8.41
W F Y L I M V A G C T S Q N E D H	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 0.00 3.06 9.18 7.14 9.18 3.06 6.12 2.04	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.29 10.28 10.28 10.29 10.28 10.28 10.28 10.29 10.28 10.29 10.28 10.28 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.28 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.29 10.21 20.41 20.56 1.88 20.93 7.48 6.54 2. 80 4.67 1.88 0.93 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 0.93 1.88 1.93 1.94 1.94 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.95 1.	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 9.18 4.08 3.06 0.00	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76 3. 76 9.34 0.93 2.80	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 8.16 8.16 0.00 5.10 6.12 3.06 4.08 6.12 7.14 2.04	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54 9.34 8.41 3.76 1.88 3.76	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06 6.12 3.06 6.12 2.04	<i>In-vitro</i> ^{c.d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66 4.67 7.48 8.41 2.80
W F Y L I M V A G C T S Q N E D H R	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 0.00 3.06 9.18 7.14 9.18 3.06 6.12 2.04 10.20	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 1.88 11.21 8.41 5.66 1.88 0.93 7.48 6.54 2.80 4.67 1.88 0.93 3.74	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 10.20 4.08 9.18 4.08 3.06 0.00 5.10	<i>In-vitro</i> ^{c.d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76 3.76 9.34 0.93 2.80 10.28	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 0.00 5.10 6.12 3.06 4.08 6.12 7.14 2.04 5.10	<i>In-vitro</i> ^{c,d} 1.88 7.48 1.88 8.41 5.66 1.88 5.66 8.41 4.67 1.88 3.76 6.54 9.34 8.41 3.76 1.88 3.76 6.54	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06 6.12 3.06 6.12 2.04 8.16	<i>In-vitro</i> ^{c,d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66 4.67 7.48 8.41 2.80 2.80
W F Y L I M V A G C T S Q N E D H R K	P1 ^{/4} <i>In-situ</i> ^{b,d} 0.00 7.14 1.02 3.06 3.06 1.02 9.18 6.12 6.12 6.12 0.00 3.06 9.18 7.14 9.18 3.06 6.12 2.04 10.20 8.16	<i>In-vitro</i> ^{c,d} 1.88 11.22 0.93 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 10.28 11.21 8.41 5. 666 1. 88 0. 93 7.48 6.54 2. 80 4. 67 1. 88 0. 93 3. 74 5. 666	P2' ^a <i>In-situ</i> ^{b,d} 0.00 4.08 6.12 6.12 4.08 1.02 7.14 8.16 9.18 1.02 4.08 10.20 4.08 9.18 4.08 9.18 4.08 3.06 0.00 5.10 5.10 5.10	<i>In-vitro</i> ^{c,d} 0.00 6.54 3.76 6.54 8.41 0.93 5.66 10.28 3.76 0.93 4.67 11.21 3.76 3.76 9.34 0.93 2.80 10.28 4.67	P3' ^a In-situ ^{b,d} 1.02 12.24 3.06 5.10 6.12 0.00 5.10 8.16 8.16 8.16 0.00 5.10 6.12 3.06 4.08 6.12 3.06 4.08 6.12 7.14 2.04 5.10 7.14	<i>In-vitro</i> ^{c.d} 1.88 7.48 1.88 8.41 5.66 8.41 4.67 1.88 3.76 6.54 9.34 8.41 3.76 6.54 9.34 8.41 3.76 6.54 9.34 8.41 3.76 6.54 9.34 8.41 3.76 6.54 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.34 8.41 9.36 9.34 8.41 9.36 9.34 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.36 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 9.56 	P4' ^a In-situ ^{b,d} 1.02 9.18 4.08 6.12 4.08 2.04 7.14 7.14 6.12 0.00 3.06 8.16 3.06 6.12 5.12 5.16	<i>In-vitro</i> ^{c.d} 0.93 7.48 0.00 5.66 4.67 0.93 8.41 8.41 6.54 0.93 3.76 7.48 5.66 4.67 7.48 5.66 4.67 7.48 8.41 2.80 2.80 6.54

^a Amino acid positions around the cleavage sites.

^b Predicted from the N-terminal and C-terminal ends of oligopeptides isolated from fermented cocoa beans [3,4].

^c Detected by *in vitro* digestion of three different protein substrates with the cocoa aspartic protease (compare Table 1).

^d Values are expressed in percent of all amino acids found in these positions. Values above 6% are marked in bold.

previously described [1,2]. 10 mg of horse myoglobin or of the individual cocoa seed proteins in 1 ml of 20 mM sodium acetate (pH 5.0) were partially digested with either 100 μ g of purified cocoa aspartic protease or 50 μ g of commercial porcine pepsin (Sigma-Aldrich Chemie, Taufkirchen, Germany). The obtained peptides were modified by reduction with dithiotreitol and subsequent alkylation of the cysteine residues with iodoacetamide before being analyzed by mass spectrometry.

Liquid chromatography-MALDI-TOF/TOF-MS/MS analyses were performed on a 4700 proteomics Analyzer (ABSCIEX, Framingham, MS) off-line coupled with an Ultimate HPLC system and Probot fractionation device (both Dionex/Thermo, Idstein, Germany). LC separations were performed on an analytical column (PepMap C18, 3 μ m, 150 mm × 75 μ m; Dionex) at a flow rate of 200 nl/min. Mobile phase (A) was 2:98 (v/v) acetonitrile/water containing 0.05% (v/v) TFA and (B) was 80:20 (v/v) acetonitrile/water containing 0.045% (v/v) TFA. Gradients were 0–10% B in 4 min, 10-50% B in 30 min, 50–100% B in 2 min. Column effluent was continuously mixed with MALDI matrix (5 mg/ml α -cyano-4-hydroxycinnamic acid in 70:30 (v/v) acetonitrile/water containing 0.1% (v/v) TFA, 1 μ l/min) and spotted at 10-s intervals on 26 × 12 spot arrays on MALDI steel targets (Applied Biosystems, Darmstadt, Germany).

Mass spectra were acquired in a data-dependent mode. The MS spectra were recorded in the mass range of m/z 800–4000 and with the accumulation of 2000 subspectra. MS/MS spectra were measured from the five most intensive precursor ions (S/N > 30). 5000–10,000 laser shots were accumulated. MS and MS/MS peak lists were generated by the "Peak to Mascot" tool of the 4000er Series Explorer v3.6. For MS/MS data analysis, MASCOT server (version 2.3, Matrixscience, London, UK) was used. Data base searches were performed using SwissProt (2015_03; 547964 protein sequences) and the following parameters: no enzyme, one missed cleavage, variable modifications: carbamidomethylation (C), oxidation (M), pyro-glu (Q), mass tolerances for MS and MS/MS: 100 ppm and 0.3 Da. Enzymatic peptides of horse myoglobin (SwissProt no. P68082), cocoa vicilin-class(7S) globulin (TrEMBL no. A0A061EM85), and the cocoa 21-kDa seed protein (SwissProt no. P32765) were accepted as identified if their MS/MS spectra provided a MASCOT score for identity with p < 0.05.

The different cleavage sites were determined by localization of the N- and C-terminal ends of the oligopeptides within the amino acid sequence of the corresponding substrate proteins. The octa-peptide sequences around the cleavage sites and their positions in the corresponding substrate proteins are listed in Table 1. Three classes of cleavage sites were found and separately listed (Table 1):

- (1) Those which were exclusively cleaved by the cocoa aspartic protease (=specific cleavage sites of the cocoa enzyme),
- (2) those which were cleaved both by the cocoa aspartic protease and pepsin (=unspecific cleavage sites of the cocoa enzyme) and
- (3) those which were exclusively cleaved by pepsin.

2.2. Determination of putative in-situ cleavage sites used during cocoa fermentation

Oligopeptides isolated from fermented cocoa beans and sequenced by ESI-MS/MS mass spectrometric analyses were taken from the literature [3,4] and used to identify the putative *in-situ* cleavage sites of the cocoa aspartic protease in the 21-kDa cocoa seed protein and in the vicilin-class(7S) globulin of the cocoa beans, respectively. The octapeptide sequences around the putative cleavage sites used in the formation of the oligopeptides isolated from fermented cocoa beans and their positions in the amino acid sequences of the 21-kDa cocoa seed protein and the cocoa vicilin-class(7S) globulin, respectively, are listed in Table 2. Since the oligopeptides generated during fermentation of the cocoa beans are more or less modified at their C-terminal ends due to the activity of a carboxypeptidase [5], prediction of the C-terminal cleavage sites is less reliable than the cleavage sites predicted from the N-terminal ends. Due to the known cleavage specificity of this particular carboxypeptidase [6], however, the putative cleavage sites corresponding to the C-terminal ends of the original cleavage products generated by the cocoa aspartic protease can be predicted with at least some reliability. When the predicted C-terminal cleavage site was assumed to be downstream from the C-terminal end of the isolated peptide, this was marked by "+CP". Up to now, 87 different oligopeptides have been isolated from fermented cocoa beans and sequenced by mass spectrometry [3,4]. All these oligopeptides were derived from the 21-kDa seed protein and the cocoa vicilin-class (7S) globulin, respectively [3,4].

From the N- and C-terminal ends of these 87 oligopeptides, 98 putative cleavage sites of the cocoa aspartic protease have been predicted (Table 2), 23 of which being identical to cleavage sites detected by *in-vitro* proteolysis (Tables 1 and 2).

To get an insight into the cleavage specificity of the cocoa aspartic protease, the relative abundance of the different amino acid residues in the P4–P4' positions around the cleavage sites have been determined (Table 3). This was done both for the cleavage sites putatively used *in-situ* (during the fermentation process) and for the cleavage sites determined by *in-vitro* proteolysis (Table 3). In the latter case, all the cleavage sites of the cocoa aspartic protease have been considered, *i.e.* without discrimination between specific and unspecific cleavage sites as done in Table 1. Considerable differences have been observed for the relative abundance of some amino acids in the P4–P4' positions between the *in-situ* (used during fermentation) and the *in-vitro* cleavage sites, respectively (Table 3). Analysis of chemical compounds by MALDI-TOF-MS used for the identification of peptide fragments generated during *in-vitro* proteolysis [1] is restricted to ions with *m/z* > 799, due to ions generated from the matrix components. As recently reported, most peptides present in fermented cocoa beans, however, have molecular masses below this limit [3,4]. Therefore, considerably more peptides and their corresponding N- and C-terminal ends can be detected and analyzed by LC-ESI-MS/MS than by LC-MALDI-TOF/TOF-MS/MS.

Transparency document. Supporting information

Supplementary data associated with this article can be found in the online version at http://dx.doi. org/10.1016/j.dib.2016.06.021.

References

- K. Janek, A. Niewienda, J. Wöstemeyer, J. Voigt, The cleavage specificity of the aspartic protease of cocoa beans involved in the generation of the cocoa-specific aroma precursors, Food Chem. 211 (2016) 320–328.
- [2] J. Voigt, H. Heinrichs, G. Voigt, D. Wrann, B. Biehl, Cocoa-specific aroma precursors are generated by proteolytic digestion oft the vicilin-like globulin of the cocoa seeds, Food Chem. 50 (1994) 177–184.
- [3] A. Marseglia, S. Sforza, A. Faccini, M. Bencivenni, G. Palla, A. Caligiani, Extraction, identification and semi-quantification of oligopeptides in cocoa beans, Food Res. Intern. 63 (2014) 382–389.
- [4] J. Voigt, K. Janek, K. Textoris-Taube, A. Niewienda, J. Wöstemeyer, Partial purification and characterisation of the peptide precursors of the cocoa-specific aroma components, Food Chem. 192 (2016) 706–713.
- [5] J. Voigt, B. Biehl, H. Heinrichs, S. Kamaruddin, S. Gaim Marsoner, A. Hugi, *In-vitro* formation of cocoa-specific aroma precursors: aroma-related peptides generated from cocoa-seed protein by co-operation of an aspartic endoprotease and a carboxypeptidase, Food Chem. 49 (1994) 173–180.
- [6] G. Bytof, B. Biehl, H. Heinrichs, J. Voigt, Specificity and stability of the carboxypeptidase activity in ripe, ungerminated seeds of *Theobroma cacao* L, Food Chem. 54 (1995) 15–21.